PRISM BioLab Co

PRISM BioLab Co R&D per Employee

The R&D Spending per Employee of PRISM BioLab Co (206A.T) as of Nov 10, 2026 is 33.63 M JPY. In the previous year, R&D Spending per Employee was 19.93 M JPY — a change of 68.75% (higher).

R&D per Employee

33.63 MJPY

YoY

68.75%

Last updated:

R&D Spending per Employee of PRISM BioLab Co is 2024 33.63 M JPY. R&D Spending per Employee of PRISM BioLab Co was 2023 19.93 M JPY. It decreases by 68.75% higher compared to the previous year.

The PRISM BioLab Co R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2022
15.64 M JPY
Jan 1, 2023
19.93 M JPY
Jan 1, 2024
33.63 M JPY
The PRISM BioLab Co R&D per Employee history
YEARR&D per EmployeeYoY
33.63 MJPY+68.75%
19.93 MJPY+27.40%
15.64 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PRISM BioLab Co Stock analysis

What does PRISM BioLab Co do? PRISM BioLab Co Ltd generates revenue through two distinct business models in the pharmaceuticals sector. The in-house development business focuses on selecting drug discovery targets and creating programs internally using their PepMetics technology platform. The joint development business collaborates with pharmaceutical companies to develop drug discovery programs leveraging their proprietary PepMetics technology. Both models utilize the company's owned drug discovery platform to create new pharmaceutical products. The company's primary clients are pharmaceutical companies seeking to develop new drugs through partnerships with PRISM BioLab's technology. PRISM BioLab's business model centers on its PepMetics technology, which serves as the foundation for both its in-house development and joint development segments. The company builds new drug discovery platforms and develops new drugs through these segments, targeting pharmaceutical companies as their main customers. The firm's research and development activities are conducted using their owned technology, which differentiates their approach in the drug discovery market. The company's revenue streams are derived from pharmaceutical companies that partner with PRISM BioLab for drug discovery programs. By utilizing their PepMetics technology platform, the company creates targeted drug discovery solutions that are developed either internally or in collaboration with pharmaceutical partners. This approach allows PRISM BioLab to generate income through both direct development efforts and collaborative projects with industry clients. PRISM BioLab Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PRISM BioLab Co stock

R&D Spending per Employee of PRISM BioLab Co is 33.63 M JPY in 2024.

R&D Spending per Employee of PRISM BioLab Co changed from 19.93 M JPY to 33.63 M JPY, representing a 68.75% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee PRISM BioLab Co since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's PRISM BioLab Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — PRISM BioLab Co

All Key Metrics — PRISM BioLab Co